Novartis AG (NYSE:NVS) is a member of the 134 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS's market value is $200.3 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for NVS puts it 15 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 109 among the 782 companies in the sector, and number 639 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. NVS has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Novartis AG (NYSE:NVS) is classified as a constituent of the 133 company Pharmaceuticals GICS industry group, which is a segment of the 781 company GICS Health Care sector. NVS has a market value of $195.5 billion which is in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 23 among the 133 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 166 among the 781 companies in the sector, and number 1,096 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.

Novartis AG (NYSE:NVS) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.

The current recommendation of Hold for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.

Novartis AG (NYSE:NVS) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS has a market value of $200.9 billion which is in the top decile in its industry group. The ranking for NVS by Portfolio Grader places it 45 among the 133 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 297 among the 782 companies in the sector, and number 2,089 in the nearly 5,000 company Portfolio Grader universe.

Currently, Novartis AG (NYSE:NVS) has a Hold using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.

The current recommendation of Hold for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for the last month.